EUVIMEDEUVIMED entdecken
Crossref

Vaginal Progesterone Is Associated with Intrahepatic Cholestasis of Pregnancy

Abraham Tsur iD, Stephanie A Leonard iD, Peiyi Kan, Imee A Datoc, Anna I Girsen, Gary M Shaw, David K Stevenson, Yasser Y El-Sayed, Maurice L Druzin, Yair J Blumenfeld

American Journal of Perinatology · 01.08.2023 · 40 (11) · 1158-1162

DOI: 10.1055/a-2081-2573 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Perinatology, erschienen am 01.08.2023. Verfasst von Abraham Tsur und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, California. Hauptthemen laut MEDLINE: Cholestasis, Intrahepatic, Premature Birth. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The frequency of intrahepatic cholestasis of pregnancy (ICP) peaks during the third trimester of pregnancy when plasma progesterone levels are the highest. Furthermore, twin pregnancies are characterized by higher progesterone levels than singletons and have a higher frequency of cholestasis. Therefore, we hypothesized that exogenous progestogens administered for reducing the risk of spontaneous preterm birth may increase the risk of cholestasis. Utilizing the large IBM MarketScan Commercial Claims and Encounters Database, we investigated the frequency of cholestasis in patients treated with vaginal progesterone or intramuscular 17α-hydroxyprogesterone caproate for the prevention of preterm birth. Study Design We identified 1,776,092 live-born singleton pregnancies between 2010 and 2014. We confirmed second and third trimester administration of progestogens by cross-referencing the dates of progesterone prescriptions with the dates of scheduled pregnancy events such as nuchal translucency scan, fetal anatomy scan, glucose challenge test, and Tdap vaccination. We excluded pregnancies with missing data regarding timing of scheduled pregnancy events or progesterone treatment prescribed only during the first trimester. Cholestasis of pregnancy was identified based on prescriptions for ursodeoxycholic acid. We used multivariable logistic regression to estimate adjusted (for maternal age) odds ratios for cholestasis in patients treated with vaginal progesterone, and in patients treated with 17α-hydroxyprogesterone caproate compared with those not treated with any type of progestogen (the reference group).

Results

The final cohort consisted of 870,599 pregnancies. Among patients treated with vaginal progesterone during the second and third trimester, the frequency of cholestasis was significantly higher than the reference group (0.75 vs. 0.23%, adjusted odds ratio [aOR]: 3.16, 95% confidence interval [CI]: 2.23–4.49). In contrast, there was no significant association between 17α-hydroxyprogesterone caproate and cholestasis (0.27%, aOR: 1.12, 95% CI: 0.58–2.16)

Conclusion

Using a robust dataset, we observed that vaginal progesterone but not intramuscular 17α-hydroxyprogesterone caproate was associated with an increased risk for ICP. Key Points

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholestasis, IntrahepaticPremature BirthProgesteroneProgestinsInfant, NewbornFemaleHumansPregnancy ComplicationsHydroxyprogesterones17 alpha-Hydroxyprogesterone CaproatePregnancy

Substanzen

Progesterone17 alpha-Hydroxyprogesterone CaproateProgestinsHydroxyprogesterones

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, California.
  • Department of Obstetrics and Gynecology, The Sheba Medical Center, Tel HaShomer, Israel and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Department of Pediatrics, Stanford University School of Medicine, Stanford, California.

ORCID-Profile: Abraham Tsur, Stephanie A Leonard

Zitieren

APA

Tsur, A., Leonard, S. A., Kan, P., Datoc, I. A., Girsen, A. I., Shaw, G. M., Stevenson, D. K., El-Sayed, Y. Y., Druzin, M. L., & Blumenfeld, Y. J. (2023). Vaginal Progesterone Is Associated with Intrahepatic Cholestasis of Pregnancy. American Journal of Perinatology, 40(11), 1158-1162. https://doi.org/10.1055/a-2081-2573

Vancouver

Tsur A, Leonard SA, Kan P, Datoc IA, Girsen AI, Shaw GM, et al. Vaginal Progesterone Is Associated with Intrahepatic Cholestasis of Pregnancy. American Journal of Perinatology. 2023;40(11):1158-1162. doi:10.1055/a-2081-2573

BibTeX
@article{Tsur2023,
  author = {Tsur, Abraham and Leonard, Stephanie A and Kan, Peiyi and Datoc, Imee A and Girsen, Anna I and Shaw, Gary M and Stevenson, David K and El-Sayed, Yasser Y and Druzin, Maurice L and Blumenfeld, Yair J},
  title = {Vaginal Progesterone Is Associated with Intrahepatic Cholestasis of Pregnancy},
  journal = {American Journal of Perinatology},
  year = {2023},
  volume = {40},
  number = {11},
  pages = {1158--1162},
  doi = {10.1055/a-2081-2573}
}
Kostenlos starten →